Deciphera Pharmaceuticals (NASDAQ:DCPH) Downgraded to Strong Sell at BidaskClub

BidaskClub lowered shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a sell rating to a strong sell rating in a report published on Tuesday morning, BidAskClub reports.

Several other analysts have also weighed in on DCPH. ValuEngine lowered shares of Deciphera Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, April 9th. Piper Jaffray Companies raised their price objective on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an overweight rating in a report on Monday, June 3rd. They noted that the move was a valuation call. Canaccord Genuity dropped their price objective on shares of Deciphera Pharmaceuticals from $55.00 to $50.00 and set a buy rating for the company in a report on Friday, March 15th. Finally, Zacks Investment Research lowered shares of Deciphera Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, February 12th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $43.88.

Shares of DCPH opened at $21.05 on Tuesday. The stock has a market cap of $837.10 million, a price-to-earnings ratio of -7.46 and a beta of 2.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.55 and a quick ratio of 9.55. Deciphera Pharmaceuticals has a 12 month low of $18.55 and a 12 month high of $45.61.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($1.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.41). As a group, sell-side analysts anticipate that Deciphera Pharmaceuticals will post -4.57 earnings per share for the current fiscal year.

In other news, CFO Thomas Patrick Kelly sold 13,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $22.93, for a total transaction of $309,555.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 17,073 shares of company stock valued at $399,388. Company insiders own 7.02% of the company’s stock.

Several institutional investors have recently modified their holdings of DCPH. Millennium Management LLC increased its holdings in shares of Deciphera Pharmaceuticals by 1,405.1% in the fourth quarter. Millennium Management LLC now owns 1,246,640 shares of the company’s stock valued at $26,167,000 after purchasing an additional 1,163,815 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Deciphera Pharmaceuticals by 73.6% in the fourth quarter. BlackRock Inc. now owns 1,173,245 shares of the company’s stock valued at $24,625,000 after purchasing an additional 497,427 shares in the last quarter. Orbimed Advisors LLC increased its holdings in shares of Deciphera Pharmaceuticals by 25.0% in the fourth quarter. Orbimed Advisors LLC now owns 2,442,200 shares of the company’s stock valued at $51,262,000 after purchasing an additional 488,700 shares in the last quarter. Norges Bank acquired a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at approximately $6,974,000. Finally, Sofinnova Investments Inc. acquired a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at approximately $5,572,000. 58.89% of the stock is owned by institutional investors and hedge funds.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Story: What can cause a stock to outperform?

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.